| anastrozole vs fulvestrant | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 1.06 [0.81 1.40] | p=1.00 | 0 | 851 | 1 | Mauriac, | | objective response (ORR) | 1.16 [0.81 1.65] | p=1.00 | 0 | 851 | 1 | Mauriac, | | progression or death (progression free survival PFS) | 1.34 [0.79 2.28] | p=1.00 | 0 | -18 | 1 | Mauriac, | | hot flushes | 0.98 [0.70 1.36] | p=1.00 | 0 | 846 | 1 | Mauriac, | | rash | 1.33 [0.74 2.40] | p=1.00 | 0 | 397 | 1 | Mauriac, | | vaginal bleeding | no data | | thromboembolic AE | 1.13 [0.56 2.30] | p=1.00 | 0 | 846 | 1 | Mauriac, | | arthralgia | no data | | vomiting | 0.91 [0.60 1.37] | p=1.00 | 0 | 846 | 1 | Mauriac, | | diarrhoea | 1.32 [0.79 2.21] | p=1.00 | 0 | 397 | 1 | Mauriac, | | nausea | 0.97 [0.71 1.32] | p=1.00 | 0 | 846 | 1 | Mauriac, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| anastrozole vs megestrol acetate | No demonstrated result diarrhoea by 217% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 0.96 [0.67 1.36] | p=1.00 | 0 | 516 | 1 | Buzdar a, | | objective response (ORR) | 0.98 [0.58 1.65] | p=1.00 | 0 | 516 | 1 | Buzdar a, | | death (overall survival) | 0.78 [0.39 1.57] | p=1.00 | 0 | -18 | 1 | Buzdar a, | | hot flushes | 1.56 [0.88 2.78] | p=1.00 | 0 | 515 | 1 | Buzdar a, | | vaginal bleeding | 0.48 [0.19 1.22] | p=1.00 | 0 | 515 | 1 | Buzdar a, | | thromboembolic AE | 0.72 [0.30 1.75] | p=1.00 | 0 | 515 | 1 | Buzdar a, | | arthralgia | no data | | rash | 0.74 [0.37 1.44] | p=1.00 | 0 | 515 | 1 | Buzdar a, | | vomiting | 1.53 [0.81 2.89] | p=1.00 | 0 | 515 | 1 | Buzdar a, | | diarrhoea | 3.17 [1.34 7.53] | p=0.04 | 0 | 515 | 1 | Buzdar a, | | nausea | 1.39 [0.85 2.26] | p=1.00 | 0 | 515 | 1 | Buzdar a, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| anastrozole vs tamoxifen | No demonstrated result suggested thromboembolic AE by 45% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 0.87 [0.69 1.09] | p=1.00 | 0 | 1259 | 2 | TARGET (Bonneterre),Milla-Santos, | | objective response (ORR) | 0.89 [0.70 1.14] | p=1.00 | 0 | 1259 | 2 | TARGET (Bonneterre),Milla-Santos, | | death (overall survival) | 0.95 [0.59 1.53] | p=1.00 | 0 | 650 | 2 | TARGET (Bonneterre),Milla-Santos, | | progression or death (progression free survival PFS) | 0.82 [0.48 1.40] | p=1.00 | 0 | 668 | 1 | TARGET (Bonneterre), | | rash | no data | | arthralgia | no data | | hot flushes | 1.15 [0.86 1.53] | p=1.00 | 0 | 1017 | 1 | TARGET (Bonneterre), | | vaginal bleeding | 0.46 [0.16 1.33] | p=1.00 | 0 | 1017 | 1 | TARGET (Bonneterre), | | thromboembolic AE | 0.55 [0.31 0.99] | p=0.04 | 0 | 1017 | 1 | TARGET (Bonneterre), | | vomiting | 1.07 [0.66 1.71] | p=1.00 | 0 | 1017 | 1 | TARGET (Bonneterre), | | diarrhoea | 1.22 [0.76 1.97] | p=1.00 | 0 | 1017 | 1 | TARGET (Bonneterre), | | nausea | 0.90 [0.66 1.22] | p=1.00 | 0 | 1017 | 1 | TARGET (Bonneterre), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
